RX HERCULINK ELITE RENAL STENT SYSTEM

FDA Premarket Approval P110001

This medical device has supplements. The device description/function or indication may have changed. Be sure to look at the supplements to get an up-to-date information on device changes. The labeling included below is the version at time of approval of the original pma or panel track supplement and may not represent the most recent labeling.

Pre-market Approval Supplement Details

Approval for the rx herculink elite renal stent system. This device is indicated for use in patients with atherosclerotic disease of the renal arteries following sub-optimal percutaneous transluminal renal angioplasty (ptra) of a de novo or restenotic atherosclerotic lesion (= 50% residual stenosis, >= 20 mmhg peak systolic or >= 10 mmhg mean translesional pressure gradient, flow-limiting dissection, or timi [thrombolysis in myocardial infarction] flow

DeviceRX HERCULINK ELITE RENAL STENT SYSTEM
Generic NameStent, Renal
ApplicantABBOTT VASCULAR
Date Received2011-01-03
Decision Date2011-07-20
Notice Date2011-08-01
PMAP110001
SupplementS
Product CodeNIN 
Docket Number11M-0564
Advisory CommitteeCardiovascular
Expedited ReviewNo
Combination Product No
Applicant Address ABBOTT VASCULAR 3200 Lakeside Drive santa Clara, CA 95054
Summary:Summary of Safety and Effectiveness
Labeling: Labeling
Post-Approval Study:Show Report Schedule and Study Progress
Approval Order: Approval Order

Supplemental Filings

Supplement NumberDateSupplement Type
P110001Original Filing
S018 2022-02-28 30-day Notice
S017 2021-11-09 30-day Notice
S016 2021-09-28 30-day Notice
S015 2021-04-29 30-day Notice
S014 2021-04-29 30-day Notice
S013 2017-03-21 30-day Notice
S012 2015-02-25 30-day Notice
S011 2013-12-11 Normal 180 Day Track No User Fee
S010 2012-12-19 30-day Notice
S009 2012-08-02 Normal 180 Day Track No User Fee
S008 2012-07-20 30-day Notice
S007 2012-06-13 30-day Notice
S006 2012-06-11 30-day Notice
S005 2012-05-24 30-day Notice
S004 2012-05-11 30-day Notice
S003 2012-04-27 Normal 180 Day Track No User Fee
S002 2011-11-21 30-day Notice
S001 2011-08-19 30-day Notice

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.